

**FOR IMMEDIATE RELEASE 9/13/04**

Contacts: Dan Rippy, HEALTHPOINT dan.rippy@healthpoint.com 1-800-441-8227
Anne M. VanLent, Barrier Therapeutics 1-609-945-1202
Mark Vincent, Euro RSCG Life NRP 1-212-845-4239

HEALTHPOINT Ltd. And Barrier Therapeutics Establish Sales and Distribution Agreement for Zimyca™ to Healthcare Institutions

Agreement Includes Development of Zimyca for an Adult Indication

(Fort Worth, TX and Princeton, NJ - September 13, 2004)... HEALTHPOINT®, Ltd., an affiliate company of DFB Pharmaceuticals, Inc., a Texas-based market leader in advanced wound care, dermatology, and surgical products, and Barrier Therapeutics, Inc. (NASDAQ: BTRX), a biopharmaceutical company developing pharmaceutical products in the field of dermatology, today announced a product development and commercialization collaboration for Zimyca™, Barrier's antifungal prescription pharmaceutical product candidate. Zimyca is a topical ointment consisting of 0.25% miconazole nitrate, an antifungal agent, in a zinc oxide and petrolatum base. Barrier is developing Zimyca for the treatment of infants with *Candida*-associated diaper dermatitis, an inflammatory disease in which an infant's diaper rash is complicated with an infection caused by the fungus called *Candida*.

Under the terms of this agreement, HEALTHPOINT will have the exclusive rights to market the product for all approved indications to healthcare institutions in the United States and Canada, including hospitals, convalescent facilities, extended and long-term care facilities, and nursing homes. Additionally, HEALTHPOINT will fund the further clinical development of Zimyca for an adult indication. Barrier will receive milestone payments and revenue from the sale of Zimyca to HEALTHPOINT, as well as the right to any new indications for the product. The specific terms of this collaboration were not disclosed.

"Aligning ourselves with the Tissue Management Division of HEALTHPOINT provides Barrier with an additional opportunity to maximize the commercial potential of Zimyca by enabling us to expand our reach into the institutional healthcare segment," said Al Altomari, Chief Commercial Officer of Barrier Therapeutics. "Additionally, HEALTHPOINT's expertise in tissue management for adult and elderly patients makes them the ideal partner for developing Zimyca for an adult indication and distributing the product to this patient group."

"Zimyca has the potential to offer a formulation that is specifically designed for the needs of an adult population, and this agreement will enable HEALTHPOINT to pursue its development for this important market," said Michael Steadman, President of Tissue Management at HEALTHPOINT.

"The agreement allows Barrier Therapeutics and HEALTHPOINT to employ complementary strengths for further developing Zimyca according to the needs of the patients themselves, both inside and outside the hospital environment," added Mr. Steadman.

Barrier has completed a Phase III clinical trial for the use of Zimyca in the treatment of infants with proven *Candida*-associated diaper dermatitis to support a New Drug Application (NDA) in the United States. Barrier recently announced that in that study, Zimyca achieved statistical significance versus vehicle for all primary and secondary endpoints. This study will form the basis of the filing of an amendment to Barrier's pending NDA. The Company plans to file this amendment before the end of 2004. (more)

The product has received marketing approval from the Belgian Health Authorities and is the subject of a Mutual Recognition Procedure for approval in the major markets of Europe.

About HEALTHPOINT

Since its inception in 1992, HEALTHPOINT has established a U.S. presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices for tissue management, dermatology, and surgical. An aggressive research and development effort has brought HEALTHPOINT's unique technologies to the market, setting the pace for its highly trained field sales organization of direct sales representatives. HEALTHPOINT, with over 290 employees, is a DFB Pharmaceuticals, Inc. affiliate company. HEALTHPOINT is based in Fort Worth, Texas. Visit HEALTHPOINT's web site at www.healthpoint.com. Also headquartered in Fort Worth, DFB provides technology-driven products, outsourcing services, and licensing opportunities to the healthcare industry worldwide through its affiliate companies, contract partners, and branded marketing organizations.

About Barrier

Barrier Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative pharmaceutical products to treat diseases of the skin. The Company has eight product candidates in various stages of clinical development. The four most advanced product candidates, which are in or entering Phase III clinical trials, are under development for the treatment of *Candida*-associated diaper dermatitis, seborrheic dermatitis, fungal infections, including vaginal candidiasis and onychomycosis, and congenital ichthyosis. Barrier has product candidates in earlier stages of clinical development for the treatment of acne, psoriasis, fungal infections, allergies and dermatitis. The Company is headquartered in Princeton, New Jersey and has a wholly-owned subsidiary in Geel, Belgium. Visit Barrier's web site at <http://www.barriertherapeutics.com>. Safe Harbor Statement: In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements regarding the timing for making regulatory filings, the development of any additional indications and the market prospects for Barrier's product. Forward-looking statements provide Barrier's current expectations or forecasts of future events. Barrier's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries. For a discussion of these and other risks and uncertainties that may effect the forward-looking statements please see the risk factors in Form 10-Q for the quarterly period ended June 30, 2004, which is on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Barrier undertakes no obligation to update publicly any forward-looking statement.

###